Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Depreciation & Amortization (CF) (2016 - 2025)

Angiodynamics (ANGO) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 16.26% year-over-year to $5.7 million, compared with a TTM value of $23.9 million through Nov 2025, down 14.54%, and an annual FY2025 reading of $25.8 million, down 6.9% over the prior year.
  • Depreciation & Amortization (CF) was $5.7 million for Q4 2025 at Angiodynamics, down from $6.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $7.8 million in Q1 2023 and bottomed at $5.7 million in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $6.9 million, with a median of $6.8 million recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) grew 17.52% in 2022, then dropped 16.26% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $7.3 million in 2021, then grew by 7.4% to $7.8 million in 2022, then decreased by 14.49% to $6.7 million in 2023, then rose by 2.66% to $6.9 million in 2024, then decreased by 16.26% to $5.7 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ANGO at $5.7 million in Q4 2025, $6.0 million in Q3 2025, and $5.8 million in Q2 2025.